Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors
- PMID: 30549490
- PMCID: PMC6296258
- DOI: 10.4088/JCP.18m12331
Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors
Abstract
Objective: Late-life depression has been associated with increased risk of mild cognitive impairment (MCI) and dementia. Predictors of increased risk are incompletely understood. Identification of potentially modifiable risk factors could facilitate prevention of MCI and dementia. This study aimed to determine which clinical characteristics are associated with increased risk of MCI among older adults with depression and normal cognition at baseline.
Methods: Data from the National Alzheimer's Coordinating Center dataset were used. Study participants who attended a participating Alzheimer's Disease Center from September 2005 through September 2017 with normal cognition and a history of clinically defined depression (broadly based on DSM criteria) were followed until first diagnosis of MCI (or dementia when MCI was not diagnosed).
Results: A total of 2,655 study participants were followed for a median duration of 41.8 months. Of these, 586 (22.1%) developed either MCI (n = 509, 19.2%) or dementia (n = 77, 2.9%). In survival analyses, cognitive decline was associated with age, sex, education, baseline cognition, and several potentially modifiable risk factors including vascular risk factors, hearing impairment, vitamin B₁₂ deficiency, active depression within the last 2 years, and increased severity of depression. In an adjusted survival analysis, the only variables that remained significantly associated with development of MCI or dementia were female sex (HR = 0.72; 95% CI, 0.59-0.88), higher education (HR = 0.96; 95% CI, 0.93-0.99), and higher baseline cognition (HR = 0.87; 95% CI, 0.82-0.93), which were associated with reduced risk, and older age (HR = 1.07; 95% CI, 1.05-1.08), active depression within the last 2 years (HR = 1.41; 95% CI, 1.15-1.74), and increased severity of depression (HR = 1.05; 95% CI, 1.02-1.09), which were associated with increased risk.
Conclusions: Development of MCI is associated with several potentially modifiable risk factors in older adults with depression. Future studies should determine whether active management of risk factors could reduce incidence of MCI in this vulnerable population.
© Copyright 2018 Physicians Postgraduate Press, Inc.
Conflict of interest statement
Conflicts of Interest:
NH has received consultation fees from Pfizer, Lilly, Merck & Astellas. KL has received grant support from AbbVie, Axovant & advisory board fees from Lundbeck, Otsuka & Novartis. DG and AK have no conflicts to declare.
References
-
- Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009. April;119(4):252–265. - PubMed
-
- Gallagher D, Savva GM, Kenny R, Lawlor BA. What predicts persistent depression in older adults across Europe? Utility of clinical and neuropsychological predictors from the SHARE study. J Affect Disord 2013. May;147(1–3):192–197. - PubMed
-
- Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005. August 1;58(3):204–210. - PubMed
Publication types
MeSH terms
Grants and funding
- P30 AG013854/AG/NIA NIH HHS/United States
- P30 AG053760/AG/NIA NIH HHS/United States
- P30 AG010124/AG/NIA NIH HHS/United States
- P50 AG023501/AG/NIA NIH HHS/United States
- P50 AG005142/AG/NIA NIH HHS/United States
- P50 AG005131/AG/NIA NIH HHS/United States
- P30 AG010133/AG/NIA NIH HHS/United States
- P50 AG016574/AG/NIA NIH HHS/United States
- P50 AG005146/AG/NIA NIH HHS/United States
- P30 AG035982/AG/NIA NIH HHS/United States
- P50 AG008702/AG/NIA NIH HHS/United States
- U01 AG016976/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
- P30 AG013846/AG/NIA NIH HHS/United States
- P50 AG047270/AG/NIA NIH HHS/United States
- P50 AG005136/AG/NIA NIH HHS/United States
- P30 AG049638/AG/NIA NIH HHS/United States
- P30 AG012300/AG/NIA NIH HHS/United States
- P50 AG016573/AG/NIA NIH HHS/United States
- P50 AG047266/AG/NIA NIH HHS/United States
- P50 AG005134/AG/NIA NIH HHS/United States
- P30 AG008017/AG/NIA NIH HHS/United States
- P30 AG010161/AG/NIA NIH HHS/United States
- P50 AG025688/AG/NIA NIH HHS/United States
- P50 AG005133/AG/NIA NIH HHS/United States
- P50 AG005138/AG/NIA NIH HHS/United States
- P50 AG047366/AG/NIA NIH HHS/United States
- P30 AG010129/AG/NIA NIH HHS/United States
- P30 AG019610/AG/NIA NIH HHS/United States
- P30 AG028383/AG/NIA NIH HHS/United States
- P50 AG033514/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical